XAGE1A
X antigen family member 1
Also known as: CT12.1a, CT12.1b, CT12.1c, CT12.1d, GAGED2, XAGE-1, XAGE1, XAGE1_HUMAN, XAGE1B, XAGE1C, XAGE1D, XAGE1E
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HD64
- Gene
- XAGE1A
- Ensembl
- ENSG00000204379
- Chromosome
- X
- Canonical length
- 81 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
This gene is a member of the XAGE subfamily, which belongs to the GAGE family. The GAGE genes are expressed in a variety of tumors and in some fetal and reproductive tissues. This gene is strongly expressed in Ewing's sarcoma, alveolar rhabdomyosarcoma and normal testis. The protein encoded by this gene contains a nuclear localization signal and shares a sequence similarity with other GAGE/PAGE proteins. Because of the expression pattern and the sequence similarity, this protein also belongs to a family of CT (cancer-testis) antigens. Alternative splicing of this gene, in addition to alternative transcription start sites, results in multiple transcript variants. [provided by RefSeq, Jan 2010]
Canonical amino-acid sequenceUniProt
81 residues, UniProt reviewed canonical sequence.
>Q9HD64|XAGE1A
1 MESPKKKNQQ LKVGILHLGS RQKKIRIQLR SQCATWKVIC KSCISQTPGI NLDLGSGVKV
61 KIIPKEEHCK MPEAGEEQPQ VLocalizationUniProt · AlphaFold · HPA
Whether an antibody against XAGE1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.51
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- testis: 44 nTPM
- adipose tissue: 0.1 nTPM
- lymph node: 0.1 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
Single-cell type
- undifferentiated spermatogonia: 2.2 nCPM
- early primary spermatocytes: 1 nCPM
- differentiating spermatogonia: 0.7 nCPM
- alveolar cells type 2: 0.6 nCPM
- transitional alveolar cells: 0.5 nCPM
- cdc: 0.2 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about XAGE1A.
Disease | ImmuneIEDB
Conditions an epitope on XAGE1A was assayed in.
- lung adenocarcinoma B and T cell
- melanoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against XAGE1A are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for XAGE1A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer.
2021 · Clin Chim Acta · RCR 0.6 · 11 citations - Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
2023 · Adv Clin Chem · RCR 0.2 · 2 citations - Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer.
2024 · Cancer Treat Res Commun · RCR 0.1 · 1 citations
Reference: B cellIEDB
1 publication
- Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma.
2015 · Cancer Immunol Immunother · RCR 0.4 · 15 citations
Reference: T cellIEDB
1 publication
- Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads XAGE1A as an antibody target. Whether an autoantibody or antibody against XAGE1A could matter depends on whether native XAGE1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
XAGE1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label XAGE1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...